VRVappu Rantalaiho

Vappu Rantalaiho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vappu Rantalaiho has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early Targeted Combination Treatment With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs and Long‐Term Outcomes in Rheumatoid Arthritis: Ten‐Year Follow‐Up Results of a Randomized Clinical Trial

    by Vappu Rantalaiho, Tia Sandström, Juhani Koski, Pekka Hannonen, Timo Möttönen, Oili Kaipiainen‐Seppänen, Timo Yli‐Kerttula, Markku J. Kauppi, Toini Uutela, Timo Malmi, et al.

    Objective: The short‐term outcomes of remission‐targeted treatments of rheumatoid arthritis (RA) are well‐established, but the long‐term success of such strategies is speculative, as is the role of early add‐on biologics. We assessed the 10‐year outcomes of patients with early RA treated with initial remission‐targeted triple combination of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), 7.5‐mg prednisolone, and additional infliximab (IFX) or placebo infusions.Methods: Ninety‐nine patients with early, DMARD‐naive RA were treated with a triple combination of csDMARDs and prednisolone and randomized to double‐blind receipt of infusions of either IFX (the Finnish Rheumatoid Arthritis Combination Therapy Trial [FIN‐RACo] + IFX) or placebo (FIN‐RACo + placebo) during the first 6 months. After 2 years, the treatment strategies became unrestricted, but the treatment goal was strict remission in the TNF‐Blocking Therapy in Combination With Disease‐Modifying Antirheumatic Drugs in Early Rheumatoid Arthritis (NEO‐RACo) study. At 10 years, the clinical and radiographic outcomes and the drug treatments used between 5 and 10 years were assessed.Results: Ninety patients (91%) were followed after 2 years, 43 in the FIN‐RACo + IFX and 47 in the FIN‐RACo + placebo group. At 10 years, the respective proportions of patients in strict NEO‐RACo remission and in Disease Activity Score using 28 joints remission in the FIN‐RACo + IFX and FIN‐RACo + placebo groups were 46% and 38% (P = 0.46) and 82% and 72% (P = 0.29), respectively. The mean total Sharp/van der Heijde score was 9.8 in the FIN‐RACo + IFX and 7.3 in the FIN‐RACo + placebo group (P = 0.34). During the 10‐year follow‐up, 26% of the FIN‐RACo + IFX group and 30% of the FIN‐RACo + placebo group had received biologics (P = 0.74).Conclusion: In early RA, excellent results can be maintained up until 10 years in most patients treated with initial combination csDMARDs and remission‐targeted strategy, regardless of initial IFX/placebo infusions.


  • Open Access

    Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

    by Vappu Rantalaiho, Markku Korpela, Leena Laasonen, Hannu Kautiainen, Salme Järvenpää, Pekka Hannonen, Marjatta Leirisalo-Repo, Harri Blåfield, Kari Puolakka, Anna Karjalainen, et al.

    Introduction: Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years. The aim of this study was to evaluate the radiologic progression beyond that time in patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or a single DMARD. Methods: A cohort of 199 patients with early active RA were initially randomized to receive treatment with a combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN-RACo), or treatment with a single DMARD (initially, sulfasalazine) with or without prednisolone (SINGLE). After 2 years, the drug-treatment strategy became unrestricted, but still targeted remission. The radiographs of hands and feet were analyzed by using the Larsen score at baseline, 2, 5, and 11 years, and the radiographs of large joints, at 11 years. Results: Sixty-five patients in the FIN-RACo and 65 in the SINGLE group had radiographs of hands and feet available at baseline and at 11 years. The mean change from baseline to 11 years in Larsen score was 17 (95% CI, 12 to 26) in the FIN-RACo group and 27 (95% CI, 22 to 33) in the SINGLE group (P = 0.037). In total, 87% (95% CI, 74 to 94) and 72% (95% CI, 58 to 84) of the patients in the FIN-RACo and the SINGLE treatment arms, respectively, had no erosive changes in large joints at 11 years. Conclusions: Targeting to remission with tight clinical controls results in low radiologic progression in most RA patients. Patients treated initially with a combination of DMARDs have less long-term radiologic damage than do those treated initially with DMARD monotherapy. Trial registration: Current Controlled Trials ISRCTN18445519.